全文获取类型
收费全文 | 923篇 |
免费 | 94篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 70篇 |
妇产科学 | 10篇 |
基础医学 | 118篇 |
口腔科学 | 43篇 |
临床医学 | 94篇 |
内科学 | 156篇 |
皮肤病学 | 33篇 |
神经病学 | 72篇 |
特种医学 | 220篇 |
外科学 | 46篇 |
综合类 | 39篇 |
预防医学 | 47篇 |
眼科学 | 4篇 |
药学 | 37篇 |
肿瘤学 | 51篇 |
出版年
2021年 | 6篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 10篇 |
2017年 | 6篇 |
2016年 | 13篇 |
2015年 | 11篇 |
2014年 | 25篇 |
2013年 | 20篇 |
2012年 | 19篇 |
2011年 | 23篇 |
2010年 | 34篇 |
2009年 | 26篇 |
2008年 | 35篇 |
2007年 | 20篇 |
2006年 | 30篇 |
2005年 | 14篇 |
2004年 | 17篇 |
2003年 | 14篇 |
2002年 | 7篇 |
2001年 | 14篇 |
2000年 | 10篇 |
1999年 | 15篇 |
1998年 | 39篇 |
1997年 | 44篇 |
1996年 | 40篇 |
1995年 | 36篇 |
1994年 | 26篇 |
1993年 | 32篇 |
1992年 | 31篇 |
1991年 | 21篇 |
1990年 | 20篇 |
1989年 | 26篇 |
1988年 | 36篇 |
1987年 | 49篇 |
1986年 | 26篇 |
1985年 | 21篇 |
1984年 | 10篇 |
1983年 | 17篇 |
1982年 | 14篇 |
1981年 | 21篇 |
1980年 | 17篇 |
1979年 | 10篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 22篇 |
1975年 | 10篇 |
1927年 | 4篇 |
1926年 | 4篇 |
1881年 | 4篇 |
排序方式: 共有1041条查询结果,搜索用时 15 毫秒
11.
12.
The plasma clotting factors used to treat hemophiliacs who have developed inhibitory antibodies have a shared history of limited clinical safety and utility. To improve on existing bypass factors, we have developed a reversibly acylated form of human plasma factor Xa capable of providing a time-dependent release of procoagulant activity. Factor Xa was treated with p-amidinophenyl p'-anisate to generate anisoyl Xa. The chemical modification of the protein involves acylation of the active site serine residue of factor Xa. Anisoyl Xa deacylated in a time, pH, and temperature-dependent manner. Active factor Xa generated on deacylation of anisoyl Xa exhibited amidolytic and prothrombinase complex activities in in vitro assays, the level being comparable to those of untreated factor Xa. When Anisoyl Xa was infused into rabbits, active factor Xa was generated on deacylation of the acylated enzyme, which shortened the activated partial thromboplastin time (APTT) in a dose-dependent manner. The duration of effect on rabbit APTT could be directly correlated to the level of human plasma factor Xa. Because anisoyl Xa bypasses the "tenase" complex that is compromised in hemophilia A and B and is unaffected by inhibitory antibodies, it has the potential to be used as an effective bypass therapy. 相似文献
13.
14.
BACKGROUND: The risk of hemorrhagic complications after extracorporeal shock-wave lithotripsy (ESWL) increases in patients with aspirin intake, but the hematoma-inducing mechanism has not been understood completely at the ultrastructural level. METHODS: The effect off shock-waves on the kidneys of male Wistar-rats (n=24) was investigated in an experimental setting using a special ESWL device. Ultrastructural examination was performed by light-, transmission electron- and scanning electron microscopy. RESULTS: Shock-wave induced tissue damage appeared in all kidneys independently of aspirin intake. Endothelial detachment, lethal cell injury, gaps and mechanical disruption of the glomerular basement membrane were regularly found. After 1 week, repair processes were completed with evidence of permanent fibrosis in some cases. CONCLUSIONS: ESWL can induce modest as well as fatal damage to renal tissue cells. Therefore, after an ESWL-induced hematoma a second ESWL should not be performed within 1 week of the first treatment. 相似文献
15.
16.
Monoclonal antibodies to human platelet glycoprotein IIb beta that initiate distinct platelet responses 总被引:1,自引:0,他引:1
Hybridomas secreting monoclonal antibodies (MoAbs) to human platelet membrane glycoprotein IIb (GPIIb) were prepared by fusing cells of a mouse myeloma line to spleen cells from a BALB/c mouse immunized with purified GPIIb. Six of the hybridomas secreted MoAbs that recognized epitopes on the 23,000-dalton, disulfide-linked subunit of GPIIb, GPIIb beta. All six of these MoAbs agglutinated platelets in the absence of calcium. The agglutination titers of three of the MoAbs, however, were enhanced between 2 and 6 log2 dilutions when titrated in the presence of mmol/L of calcium. The enhancement in titer was the result of MoAb- induced platelet activation followed by platelet aggregation, a reaction that could also be initiated by the monovalent Fab fragments prepared from one of the MoAbs. The MoAbs did not significantly agglutinate platelets from patients with Glanzmann's thrombasthenia, confirming biochemical evidence that there is a paucity of GPIIb beta in the membranes of these cells. Our results show that MoAbs to epitopes on GPIIb beta initiate distinct platelet responses; therefore, they should be useful for studying the ways in which regions of surface glycoproteins are involved in platelet-platelet interactions. In addition, these reagents may prove of value in diagnosing and typing patients with Glanzmann's thrombasthenia. 相似文献
17.
Stephens RW; Golder JP; Fayle DR; Hume DA; Hapel AJ; Allan W; Fordham CJ; Doe WF 《Blood》1985,66(2):333-337
Adherent monolayer cultures of human blood monocytes, peritoneal macrophages, bone marrow macrophages, and colonic mucosa macrophages were examined for their ability to produce and secrete minactivin, a specific inactivator of urokinase-type plasminogen activator. All except colonic mucosa macrophages produced and secreted appreciable amounts of minactivin, but only blood monocytes were stimulated by muramyl dipeptide (adjuvant peptide) to increase production. The minactivin from each of these populations could be shown to preferentially inhibit urokinase-type plasminogen activator and not trypsin, plasmin, or "tissue"-type plasminogen activator (HPA66). A plasminogen-activating enzyme present in monocyte cultures appeared unaffected by the presence of minactivin and could be shown to be regulated independently by dexamethasone. 相似文献
18.
Jennifer M. Logue Elisa Zucchetti Christina A. Bachmeier Gabriel S. Krivenko Victoria Larson Daniel Ninh Giovanni Grillo Biwei Cao Jongphil Kim Julio C. Chavez Aliyah Baluch Farhad Khimani Aleksandr Lazaryan Taiga Nishihori Hien D. Liu Javier Pinilla-Ibarz Bijal D. Shah Rawan Faramand Anna E. Coghill Marco L. Davila Bhagirathbhai R. Dholaria Michael D. Jain Frederick L. Locke 《Haematologica》2021,106(4):978
CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with ≥grade 3 neutropenia seen in 21 of 70 (30%) patients at day 30 and persisting in 3 of 31 (9.7%) patients at 1 year. B cells were undetectable in 30 of 34 (88.2%) patients at day 30, but were detected in 11 of 19 (57.9%) at 1 year. Median immunoglobulin G levels levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/mL at 1 year after axi-cel (n=19, range: 33– 269). In total, 23 of 85 (27.1%) patients received intravenous immunoglobulins after axi-cel, and 34 of 85 (40%) received granulocyte-colony stimulating factor. Infections in the first 30 days occurred in 31 of 85 (36.5%) patients, of which 11 of 85 (12.9%) required intravenous antibiotics or hospitalization (“severe”) and were associated with cytokine release syndrome, neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, seven severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T-cell immunosuppression without severe infection. 相似文献
19.
20.